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cardiovascular standpoint, there is evidence that low hepcidin
levels that are associated with HFE p.C282Y homozygosity,
leads to low reticuloendothelial cell iron levels despite
high total body iron and that this can lead to reduced
levels of atherosclerosis (the so called ‘‘hemochromatosis
paradox’’) [4].
2. As noted by the authors, those with SF between the ULN and
1000 lg/L had increased medical care compared to the
average person and this may have resulted in other lifestyle
changes that were beneﬁcial. For example lifestyle changes
in subjects with fatty liver disease such as diet and exercise,
can improve liver function and morbidity. No information is
given by the authors on body mass index and any changes
in this following appropriate intervention.
3. Individuals with SF between ULN and 1000 lg/L are less prone
to iron deﬁciency anemia and this may result in health beneﬁt.
The only way to answer the question of the role of venesection
therapy in HFE p.C282Y homozygotes with SF between ULN and
1000 lg/L is to do a randomized study with half the cohort
having normalization of SF and the other half not being treated.
Until such data are available, the question of beneﬁt from treating
HFE p.C282Y homozygotes with SF between ULN and 1000 lg/L
remains, in our view, unproven.
Conﬂict of interest
The authors who have taken part in this letter to the editor
declared that they do not have anything to disclose regarding
funding or conﬂict of interest with respect to this manuscript.
References
[1] Bardou-Jacquet E, Morcet J, Manet G, Laine F, Perrin M, Jouanolle AM, et al.
Decreased cardiovascular and extrahepatic cancer-related mortality in
treated patients with mild HFE hemochromatosis. J Hepatol
2015;62:682–689.
[2] Zoller H, Finkenstedt A. Should C282Y homozygotes with mild iron overload
be treated? J Hepatol 2015;62:510–511.
[3] Osborne NJ, Gurrin LC, Allen KJ, Constantine CC, Delatycki MB, McLaren CE,
et al. HFE C282Y homozygotes are at increased risk of breast and colorectal
cancer. Hepatology 2010;51:1311–1318.
[4] Sullivan JL. Do hemochromatosis mutations protect against iron-mediated
atherogenesis? Circ Cardiovasc Genet 2009;2:652–657.
Martin B. Delatycki⇑
Murdoch Childrens Research Institute, Parkville, Victoria, Australia
Austin Health, Heidelberg, Victoria, Australia⇑Corresponding author.
E-mail address: martin.delatycki@ghsv.org.au
Lyle C. Gurrin
Melbourne School of Population and Global Health,
University of Melbourne, Parkville, Victoria, Australia
Sim Yee Ong
Murdoch Childrens Research Institute, Parkville, Victoria, Australia
Grant A. Ramm
Greg J. Anderson
QIMR Berghofer Medical Research Institute, Brisbane,
Queensland, Australia
John K. Olynyk
Fiona Stanley and Fremantle Hospitals, Western Australia, Australia
Curtin University, Western Australia, Australia
Murdoch University, Western Australia, Australia
Katie J. Allen
Murdoch Childrens Research Institute, Parkville, Victoria, Australia
Royal Children’s Hospital, Parkville, Victoria, Australia
Amanda J. Nicoll
Eastern Health, Box Hill, Victoria, Australia
Lawrie W. Powell
QIMR Berghofer Medical Research Institute, Brisbane,
Queensland, Australia
JOURNAL OF HEPATOLOGY
OReply to: ‘‘Reduced mortality due to phlebotomy in moderately
iron-loaded HFE Haemochromatosis? The need for clinical trials’’- We were able to provide the amount of iron removed in 64% of
our patients. This high proportion demonstrates the efﬁcacy of
our recommendations. However, we agree that, for a signiﬁ-
cant number of patients, we had no reliable information about
long-term maintenance therapy. Therefore, we have been cau-
tious when discussing the putative role of venesection therapy
in lowering mortality rate.
- Since the early 1990s, we deliver written guidelines and a per-
sonal follow-up notebook to every C282Y homozygote. With
time, our recommendations did not vary with respect to the
indications and management of initial and maintenance ofTo the Editor:
Australian colleagues raise concerns about our study [1], and the
accompanying editorial [2]. We showed that HFE C282Y homozy-
gotes with initial serum ferritin (SF) between the upper limit of
normal and 1000 lg/L had signiﬁcantly lower overall mortality
than that of the general French population. Delatycki et al. dis-
agree with our conclusion that this could be due to early manage-
ment of patients, and putatively to the maintenance of low body
iron stores through iron removal.
With respect to their comments about methodological
aspects, we would like to stress the following points:Journal of Hepatology 2015 vol. 63 j 276–288 283
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venesection therapy [3]. They were taken back by the French
Haute Autorité de Santé [4]. Then, all our patients received
the same information about both initial and maintenance
therapy for several decades.
- Delatycki et al. discuss about morbidity aspects. However we
studied mortality and not morbidity. Fortunately a large pro-
portion of patients with breast or colon cancer do not die from
their malignancy. Thus it is not correct to compare mortality
and morbidity data. This is likely also true for cardiovascular
disease.
More importantly, iron stores in the body of patients who
were not venesected because of normal SF at diagnosis were
and remained higher than in those with moderately increased
SF who were early enrolled in a phlebotomy program. Indeed,
maintenance of SF below 50 lg/L results in lower than normal
body iron stores. Therefore, assimilating two sub-groups that
were absolutely not identical with respect to iron burden raises
serious concerns.
For all these reasons we persist to hypothesize that the dis-
crepancy in mortality data between patients with normal SF
and those with moderately increased SF strongly supports a ben-
eﬁcial role of early management of hemochromatosis. However
we agree that, as already stressed in our manuscript, we did
not demonstrate that iron removal per se was responsible for
decreasing mortality. Other factors must be discussed (lifestyle
modiﬁcations, medical follow-up etc.). Nevertheless, the fact that
patients had lower mortality when treated for mild hemochro-
matosis was well shown in this study, regardless of its precise
cause.
Finally, in our view, a randomized study of venesection
therapy in mild hemochromatosis is neither realistic nor ethical.
Moreover, the AASLD guidelines endorsed by Powell et al. do not
suggest to perform such a study and recommend that «. . . C282Y
homozygotes who have an elevated ferritin (but <1000 lg/L)
should proceed to phlebotomy . . .» [5].
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Preservation injury of the distal extrahepatic bile duct of donor
livers is representative for injury of the intrahepatic bile ducts
To the Editor:
We recently published an article in the Journal of Hepatology
describing the histology of biopsies taken from the distal end of
the extrahepatic bile duct of donor livers at the time of
transplantation [1]. This study demonstrated the presence of
severe biliary injury, characterized by loss of the lining biliary
epithelium, mural stroma necrosis, as well as injury of the
peribiliary glands (PBG) and peribiliary vasculature. Injury of
deep PBG and peribiliary vasculature was identiﬁed as signiﬁcant
predictors of later development of non-anastomotic biliary stric-
tures (NAS) after transplantation [1]. Severe injury and loss of the
lining biliary epithelium is almost universally found in over 90%
of donor extrahepatic bile duct biopsies taken at the time of
transplantation [2,3]. The observation that the degree of injury
of PBG and vascular plexus correlates strongly with the develop-
ment of NAS after transplantation suggests that insufﬁcient
regeneration of biliary epithelial lining after liver transplanta-
tion, due to destruction of the progenitor cell niche (i.e. the
PBGs) and insufﬁcient blood supply to bile ducts, is a critical
component in the pathogenesis of NAS [1,4]. In our previous
study, as well as two other studies on bile duct histology of
donor livers, biopsies could only be obtained from the distal
end of the donor extrahepatic bile duct [2,3]. It is, however,
unknown whether the degree of injury at this level is represen-
tative for the degree of injury in the rest of the biliary tree,
including intrahepatic bile ducts.
To investigate whether histological injury detected in biopsies
taken from the distal end of a donor liver bile duct is
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